Cell-Surface Peptidases
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The cell surface has various functions: communicating with other cells, integrating into the tissue, and interacting with the extracellular matrix. Proteases play a key role in these processes. This review focuses on cell-surface peptidases (ectopeptidases, oligopeptidases) that are involved in the inactivation or activation of extracellular regulatory peptides, hormones, paracrine peptides, cytokines, and neuropeptides. The nomenclature of cell-surface peptidases is explained in relation to other proteases, and information is provided on membrane anchoring, catalytic sites, regulation, and, in particular, on their physiological and pharmacological importance. Furthermore, nonenzymatic (binding) functions and participation in intracellular signal transduction of cell surfaces peptidases are described. An overview on the different cell-surface peptidases is given, and their divergent functions are explained in detail. An example of actual pharmacological importance, dipeptidyl-peptidase IV (CD26), is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Self-citationKieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“Several studies in vitro and in vivo have shown that GLP-1 is primarily degraded at the N-terminus by the action of DPP IV resulting in biologically inactive des(His-Ala)-GLP-1 (Deacon et al., 1995a (Deacon et al., ,b, 1998a KieVer et al., 1995; Mentlein et al., 1993b) .”
BackgroundAhrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421 · cited 2×
“However, recent clinical studies with an orally active DPP IV inhibitor in type 2 diabetic patients show a considerably better insulin tolerance and improved HBA 1c levels after 4 weeks of treatment (Ahrén et al., 2002) .”
BackgroundTherapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237 · cited 1×
“Despite its multiple functions in the degradation of several regulatory peptides and the invasiveness of tumors, DPP IV is at present mainly considered a new, validated target for treatment of type 2 diabetes (Augustyns et al., 2003; Drucker, 2003b; Holst, 2002; Holst and Deacon, 1998) .”
BackgroundAbbott, C. A., McCaughan, G. W., Baker, E., & Sutherland, G. R. (1994) · Immunogenetics · doi:10.1007/bf01246674 · Cited by 177 · cited 2×
“The 5 0 -flanking domain contains neither a TATA box nor a CAAT box, but a 300-bp region extremely rich in C and G (72%) has potential binding sites for several transcription factors, such as NFkB, AP2, or Sp1 (Table V, Abbott et al., 1994; Bö hm et al., 1995) .”
BackgroundInfluentialEffect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung.
Prechel, M. M., Orawski, A. T., Maggiora, L. L., & Simmons, W. H. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12164-2 · Cited by 102
Hooper, N. M., Hryszko, J., & Turner, A. J. (1990) · Biochemical Journal · doi:10.1042/bj2670509 · Cited by 91 · cited 2×
“is located as an ectoenzyme (via a glycosyl-phosphatidylinositol anchor) on the plasma membrane of endothelial and epithelial cells whereas the soluble form is a cytosolic enzyme found in leukocytes, platelets, and brain (Harbeck and Mentlein, 1991; Hooper et al., 1990; Simmons and Orawski, 1992).”
BackgroundPrueitt, R. L., Ross, J. L., & Zinn, A. R. (2000) · Cytogenetic and Genome Research · doi:10.1159/000015560 · Cited by 91
Cited by
BARNETT, A. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01178.x · Cited by 391
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
GORRELL, M. D. (2005) · Clinical Science · doi:10.1042/cs20040302 · Cited by 334
Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94
Self-citationLost in disruption: Role of proteases in glioma invasion and progression
Mentlein, R., Hattermann, K., & Held-Feindt, J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.12.001 · Cited by 85
Self-citationHomology Modeling and Site-directed Mutagenesis of Pyroglutamyl Peptidase II
Chávez-Gutiérrez, L., Matta-Camacho, E., Osuna, J., Horjales, E., Joseph-Bravo, P., Maigret, B., & Charli, J.-L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601392200 · Cited by 21
Metadata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell-Surface Peptidases. https://app.cochat.ai/papers/10.1016/s0074-7696(04)35004-7
- The paper
- Mentlein, R. (2004). Cell-Surface Peptidases. International Review of Cytology. https://doi.org/10.1016/s0074-7696(04)35004-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.